Hutchmed China has been granted a patent for triazolopyridines and triazolopyrazines, which can be used in treating various types of cancer including lung, stomach, colorectal, and breast cancer. The compounds target c-Met inhibition and show promise in the treatment of cell proliferative disorders. GlobalData’s report on Hutchmed China gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Hutchmed China, was a key innovation area identified from patents. Hutchmed China's grant share as of February 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11896592B2) discloses a method for treating various types of cancer that are responsive to the inhibition of c-Met. The method involves administering an effective amount of at least one compound of formula 1 to a subject diagnosed with lung cancer, stomach cancer, colorectal cancer, esophageal cancer, hepatocellular cancer, breast cancer, kidney cancer, or ovarian cancer. The compounds specified in the patent claim are intended to target c-Met, a protein associated with cancer progression and metastasis.
Furthermore, the patent claims specify the selection of specific compounds of formula 1 for treating different types of cancer, including lung cancer, stomach cancer, kidney cancer, and colorectal cancer. Additionally, the use of protein tyrosine kinase inhibitors such as imatinib mesylate and gefitinib is highlighted as part of the treatment method. The patent provides a detailed framework for administering these compounds to individuals in need of treatment for c-Met responsive cancers, offering a potential avenue for personalized and targeted therapy in the field of oncology.
To know more about GlobalData’s detailed insights on Hutchmed China, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
